Early detection of progressive disease using thyroglobulin doubling-time in metastatic differentiated thyroid carcinoma treated with radioactive iodine.
Journal
Nuclear medicine communications
ISSN: 1473-5628
Titre abrégé: Nucl Med Commun
Pays: England
ID NLM: 8201017
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
pubmed:
8
2
2020
medline:
5
1
2021
entrez:
8
2
2020
Statut:
ppublish
Résumé
Detectable serum thyroglobulin (Tg) in patients with differentiated thyroid carcinoma (DTC) after total thyroidectomy indicates progression of the disease. Thyroglobulin doubling-time (TgDT) is a powerful prognostic predictor in patients with DTC. We aimed to evaluate the value of the dynamic TgDT for early detection of progressive disease (PD) in the patients of metastatic DTC with I radioactive iodine (RAI) therapy. We retrospectively evaluated 21 patients undergoing RAI therapy with metastatic DTC. Patients were defined as PD or non-PD according to Response Evaluation Criteria in Solid Tumors 1.1. TgDT was calculated by Excel-based software using Tg values measured during routine follow-up. Whole data (WDT), initial four data (IDT) and recent four data (RDT) of TgDT after total thyroidectomy were calculated and compared. Among the 21 patients (10 men; median age, 62 years old; range, 33-80), 11 patients were classified into PD and 10 were into non-PD. The initial Tg after total thyroidectomy showed a significant difference between PD and non-PD patients (P = 0.013). Short WDT, IDT and RDT (less than one year) showed a high correlation with PD (P < 0.05). RDT showed the highest predictive value for PD (P < 0.001). All the 11 PD patients showed RDT less than one year before PD (median follow-up, 157 days; range, 88-252). RDT is a powerful PD predictor in patients with metastatic DTC. Dynamic monitoring of RDT should be applied for the early detection of PD in clinic.
Identifiants
pubmed: 32032192
doi: 10.1097/MNM.0000000000001154
pii: 00006231-202004000-00009
doi:
Substances chimiques
Iodine Radioisotopes
0
Iodine-131
0
Thyroglobulin
9010-34-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
350-355Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017; 67:7–30
Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016; 388:2783–2795
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 american thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016; 26:1–133
Evans C, Tennant S, Perros P. Serum thyroglobulin in the monitoring of differentiated thyroid cancer. Scand J Clin Lab Invest Suppl. 2016; 245:S119–S123
Krejbjerg A, Bjergved L, Bülow Pedersen I, Carlé A, Knudsen N, Perrild H, et al. Serum thyroglobulin as a biomarker of iodine deficiency in adult populations. Clin Endocrinol (Oxf). 2016; 85:475–482
Miyauchi A, Kudo T, Miya A, Kobayashi K, Ito Y, Takamura Y, et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid. 2011; 21:707–716
Yazici P, Mihmanli M, Bozkurt E, Ozturk FY, Uludag M. Which is the best predictor of thyroid cancer: thyrotropin, thyroglobulin or their ratio? Hormones (Athens). 2016; 15:256–263
Rössing RM, Jentzen W, Nagarajah J, Bockisch A, Görges R. Serum thyroglobulin doubling time in progressive thyroid cancer. Thyroid. 2016; 26:1712–1718
Kelders A, Kennes LN, Krohn T, Behrendt FF, Mottaghy FM, Verburg FA. Relationship between positive thyroglobulin doubling time and 18F-FDG PET/CT-positive, 131I-negative lesions. Nucl Med Commun. 2014; 35:176–181
Giovanella L, Trimboli P, Verburg FA, Treglia G, Piccardo A, Foppiani L, Ceriani L. Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2013; 40:874–880
Higuchi T, Tomonaga H, Tokue A, Arisaka Y, Takata D, Fujii T, et al. Retrospective evaluation of the utility of thyroglobulin doubling time in the diagnosis of radioactive-iodine-refractory differentiated thyroid cancer: initial experience from 6 patients treated with Lenvatinib. 2016The 11th Symposium of Japanese Scandinavian Radiological SocietyTokyop. 35
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45:228–247
Cho SW, Choi HS, Yeom GJ, Lim JA, Moon JH, Park DJ, et al. Long-term prognosis of differentiated thyroid cancer with lung metastasis in korea and its prognostic factors. Thyroid. 2014; 24:277–286
Hirsch D, Levy S, Tsvetov G, Gorshtein A, Slutzky-Shraga I, Akirov A, et al. Long-Term outcomes and prognostic factors in patients with differentiated thyroid cancer and distant metastases. Endocr Pract. 2017; 23:1193–1200
Wang R, Zhang Y, Tan J, Zhang G, Zhang R, Zheng W, He Y. Analysis of radioiodine therapy and prognostic factors of differentiated thyroid cancer patients with pulmonary metastasis: an 8-year retrospective study. Medicine (Baltimore). 2017; 96:e6809
Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard Ba G, et al.; British Thyroid Association. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014; 81Suppl 11–122
Wang J, Liu B, Zhao Z, Kuang A. Bone metastasis from thyroid cancer diagnosed by I-131 whole-body scan without identifiable lesion in the thyroid. Clin Nucl Med. 2011; 36:1033–1035
Ciarallo A, Marcus C, Taghipour M, Subramaniam RM. Value of fluorodeoxyglucose PET/computed tomography patient management and outcomes in thyroid cancer. PET Clin. 2015; 10:265–278
Marcus C, Antoniou A, Rahmim A, Ladenson P, Subramaniam RM. Fluorodeoxyglucose positron emission tomography/computerized tomography in differentiated thyroid cancer management: importance of clinical justification and value in predicting survival. J Med Imaging Radiat Oncol. 2015; 59:281–288
Haslerud T, Brauckhoff K, Reisæter L, Küfner Lein R, Heinecke A, Varhaug JE, Biermann M. F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis. Acta Radiol. 2016; 57:1193–1200
Kim HS, Goh MJ, Kim N, Choi CG, Kim SJ, Kim JH. Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility. Radiology. 2014; 273:831–843
Beastall GH. Guidelines for management of thyroid cancer in adults: implications for clinical biochemistry. Ann Clin Biochem. 2003; 40:435–438
Persoon AC, Links TP, Wilde J, Sluiter WJ, Wolffenbuttel BH, van den Ouweland JM. Thyroglobulin (tg) recovery testing with quantitative tg antibody measurement for determining interference in serum tg assays in differentiated thyroid carcinoma. Clin Chem. 2006; 52:1196–1199
Pitoia F, Jerkovich F. Selective use of sorafenib in the treatment of thyroid cancer. Drug Des Devel Ther. 2016; 10:1119–1131
Hewett Y, Ghimire S, Farooqi B, Shah BK. Lenvatinib - a multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer. J Oncol Pharm Pract. 2018; 24:28–32
Haugen BR, Sawka AM, Alexander EK, Bible KC, Caturegli P, Doherty GM, et al. American thyroid association guidelines on the management of thyroid nodules and differentiated thyroid cancer task force review and recommendation on the proposed renaming of encapsulated follicular variant papillary thyroid carcinoma without invasion to noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Thyroid. 2017; 27:481–483